AER101 for NSCLC

(AER101 Trial)

This trial aims to determine if a new treatment, AER101, can reduce glycolysis (the process by which cells break down sugar) in individuals with non-small cell lung cancer (NSCLC). Participants will use a nebulizer, a device that turns medicine into a mist for inhalation, to self-administer AER101 three times daily for 14 days before their lung cancer surgery. The trial seeks individuals recently diagnosed with lung adenocarcinoma or squamous cell carcinoma who are planning surgery. As an Early Phase 1 trial, this research focuses on understanding how AER101 functions in people, offering participants the opportunity to be among the first to receive this new treatment.

A previous study tested AER101 for safety in patients with non-small cell lung cancer (NSCLC). However, detailed safety results are not yet available. Since this trial is in an early stage, the primary goal is to understand how the treatment works rather than thoroughly test its safety.

Early-phase trials mark the first time a treatment is tried in humans, so information on how well people tolerate it is limited. Participants will use a nebulizer to inhale AER101, which aims to target lung tumors directly. This method may help reduce side effects compared to treatments that affect the whole body.

Unlike the standard treatments for non-small cell lung cancer (NSCLC), which often involve systemic chemotherapy or targeted therapies, AER101 is administered directly to the lungs through a nebulizer. This delivery method allows for higher concentrations of the drug to reach the lung tissue directly, potentially improving its effectiveness while reducing systemic side effects. Researchers are excited about AER101 because it represents a more targeted approach, potentially offering quicker symptom relief and better tolerability for patients.

Research has shown that AER101 is designed to reduce the way cells use sugar for energy, a process called glycolysis. This is important because many lung cancers, such as non-small cell lung cancer (NSCLC), rely on this process to grow. By stopping glycolysis, AER101 might slow or halt tumor growth. In this trial, participants will receive AER101 delivered directly to the lungs with a nebulizer, which early results suggest could effectively target lung tumors. Although direct human data on AER101 is limited, the approach is based on strong scientific principles related to how cancer cells obtain energy.⁴⁵⁶⁷⁸